In Global Health Research, Is It Legitimate To Stop Clinical Trials Early on Account of Their Opportunity Costs?

article has not abstract

Vyšlo v časopise: In Global Health Research, Is It Legitimate To Stop Clinical Trials Early on Account of Their Opportunity Costs?. PLoS Med 6(6): e32767. doi:10.1371/journal.pmed.1000071
Kategorie: The PLoS Medicine Debate
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1000071

Souhrn

article has not abstract

Zdroje

1. [No authors listed] 2007 Trial and failure. Nature 446 1

2. GrossM

2004 HIV topical microbicides: Steer the ship or run aground. Am J Pub Health 94 1085 1089

3. HarrisonPF

2003 By way of introduction. Microbicide Quarterly 1: 1-4. Available: http://www.microbicide.org/galleries/tmq/tmq_apr_jun2003_final.pdf. Accessed 27 April 2009

4. Forum for Collaborative HIV Research 2007 A new era for HIV prevention? Report of the Forum for Collaborative HIV Research Biomedical Interventions of HIV Prevention Working Group September 2006 Meeting. Washington D.C.: Department of Prevention and Community Health, The George Washington University School of Public Health and Health Services. Available: http://www.hivforum.org/storage/hivforum/documents/FINAL20REPORT20ML20020907.pdf. Accessed 27 April 2009

5. AlonsoPL

SacarlalJ

AponteJJ

LeachA

MaceteE

2004 Efficacy of the RTS, S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: Randomized controlled trial. Lancet 364 1411 1420

6. AponteJJ

AideP

RenomM

MandomandoI

BassatQ

2007 Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: A double blind randomized controlled phase I/IIb trial. Lancet 370 1523 1524

7. HillAV

2006 Pre-erythrocytic malaria vaccines: Towards greater efficacy. Nat Rev Immun 6 21 32

8. MullenGED

EllisRD

MiuraK

MalkinE

NolanC

2008 Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: An asexual blood-stage vaccine for Plasmodium falciparum malaria. PLoS ONE 3 e2940 doi:10.1371/journal.pone.0002940

9. PATH 2008 July 30 $48 billion global AIDS plan becomes law: New PEPFAR bill boosts lifesaving services, encourages support for research and development. Available: http://www.path.org/news/an080730-pepfar.php. Accessed 27 April 2009

10. BerndtER

HurvitzJA

2005 Vaccine advance-purchase agreements for low-income countries: Practical issues. Health Aff 24 653 665

11. DickersonK

RennieD

2003 Registering clinical trials. JAMA 290 516 523

12. SlutskyAS

LaveryJV

2004 Data safety and monitoring boards. N Engl J Med 350 1143 1147

13. MartinDK

SingerPA

2007 Priority setting.

SingerPA

ViensA

Bioethics for clinicians Cambridge Cambridge University Press

14. DanielsN

2000 Accountability for reasonableness. BMJ 321 1300 1301

15. DanielsN

SabinJE

1997 Limits to health care: Fair procedures, democratic deliberation and the legitimacy problem for insurers. Philos Public Aff 26 303 350

16. DanielsN

SabinJE

2002 Setting limits fairly: Can we learn to share medical resources? Oxford Oxford University Press 208

17. CohenJ

1994 Pluralism and proceduralism. Chicago-Kent Law Review 69 589 618

18. RawlsJ

1993 Political liberalism New York Columbia University Press 576

19. DAMOCLESE Study Group 2005 A proposed charter for clinical trial data monitoring committees: Helping them to do their job well. Lancet 365 711 722

20. UpshurREG

2001 The ethics of alpha: Reflections on statistics, evidence and values in medicine. Theor Med Bioeth 22 565 576

21. DresserR

2001 When science offers salvation: Patient advocacy and research ethics New York Oxford University Press 232

22. HIV Prevention Trials Network 2008 HPTN 035 PRO 2000 gel trial announcement. Available: http://www.hptn.org/research_studies/HPTN035.asp. Accessed 27 April 2009